{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T21:03:46Z","timestamp":1791147826913,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["mgmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.ymgme.2014.10.012","type":"journal-article","created":{"date-parts":[[2014,10,29]],"date-time":"2014-10-29T22:49:43Z","timestamp":1414622983000},"page":"129-137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Biomarker responses correlate with antibody status in mucopolysaccharidosis type I patients on long-term enzyme replacement therapy"],"prefix":"10.1016","volume":"114","author":[{"given":"Eveline J.","family":"Langereis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"van Vlies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather J.","family":"Church","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald B.","family":"Geskus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla E.M.","family":"Hollak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon A.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Kulik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk","family":"van Lenthe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Mercer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Schreider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen L.","family":"Tylee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Wagemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frits A.","family":"Wijburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian W.","family":"Bigger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2014.10.012_bb0005","series-title":"Metab. Mol. Bases Inherit. Dis","first-page":"3421","article-title":"The mucopolysaccharidoses","author":"Neufeld","year":"2001"},{"key":"10.1016\/j.ymgme.2014.10.012_bb0010","article-title":"Enzyme replacement therapy and\/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure","volume":"55","author":"de Ru","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2014.10.012_bb0015","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1542\/peds.2007-3847","article-title":"Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I","volume":"123","author":"Clarke","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2014.10.012_bb0020","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","article-title":"Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-l-iduronidase (laronidase)","volume":"144","author":"Wraith","year":"2004","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2014.10.012_bb0025","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.amjcard.2006.02.047","article-title":"Cardiac findings after enzyme replacement therapy for mucopolysaccharidosis type I","volume":"98","author":"Braunlin","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ymgme.2014.10.012_bb0030","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ymgme.2006.08.007","article-title":"A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6years","volume":"90","author":"Sifuentes","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2014.10.012_bb0035","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1017\/S1047951109003576","article-title":"The natural course and the impact of therapies of cardiac involvement in the mucopolysaccharidoses","volume":"19","author":"Fesslov\u00e1","year":"2009","journal-title":"Cardiol. Young"},{"key":"10.1016\/j.ymgme.2014.10.012_bb0040","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1056\/NEJM200101183440304","article-title":"Enzyme-replacement therapy in mucopolysaccharidosis I","volume":"344","author":"Kakkis","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2014.10.012_bb0045","article-title":"The effectiveness and cost of enzyme replacement and substrate reduction therapies: a longitudinal cohort study of people with lysosomal storage disorders","volume":"16","author":"Wyatt","year":"2012","journal-title":"Health Technol. Assess. (Rockv)"},{"key":"10.1016\/j.ymgme.2014.10.012_bb0050","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10545-011-9444-z","article-title":"Mucopolysaccharidosis: cardiologic features and effects of enzyme-replacement therapy in 24 children with MPS I, II and VI","volume":"36","author":"Brands","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2014.10.012_bb0055","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1542\/peds.2006-2156","article-title":"Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5years: results of a multinational study of recombinant human alpha-l-iduronidase (laronidase)","volume":"120","author":"Wraith","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2014.10.012_bb0060","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/S0140-6736(03)13311-9","article-title":"Mechanisms of disease Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I","volume":"361","author":"Kakavanos","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2014.10.012_bb0065","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ymgme.2013.03.005","article-title":"Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice","volume":"109","author":"Baldo","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2014.10.012_bb0070","first-page":"2868","article-title":"Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I","volume":"118","author":"Dickson","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymgme.2014.10.012_bb0075","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.3324\/haematol.2011.058644","article-title":"Hematopoietic stem cell transplantation improves the high incidence of neutralizing allo-antibodies observed in Hurler's syndrome after pharmacological enzyme replacement therapy","volume":"97","author":"Saif","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.ymgme.2014.10.012_bb0080","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/clinchem\/35.7.1472","article-title":"Dimethylmethylene blue-based spectrophotometry of glycosaminoglycans in untreated urine: a rapid screening procedure for mucopolysaccharidoses","volume":"35","author":"de Jong","year":"1989","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ymgme.2014.10.012_bb0085","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1203\/01.PDR.0000141987.69757.DD","article-title":"Disease-specific markers for the mucopolysaccharidoses","volume":"56","author":"Fuller","year":"2004","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymgme.2014.10.012_bb0090","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ab.2007.05.016","article-title":"Analytical method for the determination of disaccharides derived from keratan, heparan, and dermatan sulfates in human serum and plasma by high-performance liquid chromatography\/turbo ionspray ionization tandem mass spectrometry","volume":"368","author":"Oguma","year":"2007","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ymgme.2014.10.012_bb0095","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s10545-012-9538-2","article-title":"Plasma and urinary levels of dermatan sulfate and heparan sulfate derived disaccharides after long-term enzyme replacement therapy (ERT) in MPS I: correlation with the timing of ERT and with total urinary excretion of glycosaminoglycans","volume":"36","author":"de Ru","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2014.10.012_bb0100","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nchembio.766","article-title":"Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses","volume":"8","author":"Lawrence","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ymgme.2014.10.012_bb0105","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/sj.bmt.1705569","article-title":"Biochemical monitoring after haemopoietic stem cell transplant for Hurler syndrome (MPSIH): implications for functional outcome after transplant in metabolic disease","volume":"39","author":"Church","year":"2007","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.ymgme.2014.10.012_bb0110","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ymgme.2006.01.005","article-title":"Heparin cofactor II-thrombin complex in MPS I: a biomarker of MPS disease","volume":"88","author":"Randall","year":"2006","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2014.10.012_bb0115","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ymgme.2009.10.175","article-title":"Evaluation of heparin cofactor II-thrombin complex as a biomarker on blood spots from mucopolysaccharidosis I, IIIA and IIIB mice","volume":"99","author":"Langford-Smith","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2014.10.012_bb0120","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s10545-010-9254-8","article-title":"Heparin cofactor II-thrombin complex and dermatan sulphate:chondroitin sulphate ratio are biomarkers of short- and long-term treatment effects in mucopolysaccharide diseases","volume":"34","author":"Langford-Smith","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2014.10.012_bb0125","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10545-011-9369-6","article-title":"Longitudinal observations of serum heparin cofactor II-thrombin complex in treated Mucopolysaccharidosis I and II patients","volume":"35","author":"Clarke","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2014.10.012_bb0130","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ymgme.2008.12.002","article-title":"Discovery of a new biomarker for the mucopolysaccharidoses (MPS), dipeptidyl peptidase IV (DPP-IV; CD26), by SELDI-TOF mass spectrometry","volume":"96","author":"Beesley","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2014.10.012_bb0135","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nmeth0408-291","article-title":"Disaccharide structure code for the easy representation of constituent oligosaccharides from glycosaminoglycans","volume":"5","author":"Lawrence","year":"2008","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ymgme.2014.10.012_bb0140","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ymgme.2008.05.001","article-title":"Heparin cofactor II-thrombin complex: a biomarker of MPS disease","volume":"94","author":"Randall","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2014.10.012_bb0145","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/glycob\/cwh076","article-title":"Glycosaminoglycans and proteoglycans in normal mitral valve leaflets and chordae: association with regions of tensile and compressive loading","volume":"14","author":"Grande-Allen","year":"2004","journal-title":"Glycobiology"},{"key":"10.1016\/j.ymgme.2014.10.012_bb0150","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1177\/34.5.3701029","article-title":"Localization of a dermatan sulfate proteoglycan (DS-PGII) in cartilage and the presence of an immunologically related species in other tissues","volume":"34","author":"Poole","year":"1986","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.ymgme.2014.10.012_bb0155","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ymgme.2013.11.015","article-title":"Early initiation of enzyme replacement therapy for the mucopolysaccharidoses","volume":"111","author":"Muenzer","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2014.10.012_bb0160","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1006\/bmme.1996.0044","article-title":"Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I","volume":"58","author":"Kakkis","year":"1996","journal-title":"Biochem. Mol. Med."},{"key":"10.1016\/j.ymgme.2014.10.012_bb0165","doi-asserted-by":"crossref","first-page":"12937","DOI":"10.1073\/pnas.91.26.12937","article-title":"Enzyme replacement in a canine model of Hurler syndrome","volume":"91","author":"Shull","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2014.10.012_bb0170","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1007\/s10545-005-0211-x","article-title":"Mucopolysaccharidosis I under enzyme replacement therapy with laronidase\u2014a mortality case with autopsy report","volume":"28","author":"Lin","year":"2005","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2014.10.012_bb0175","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1172\/JCI104532","article-title":"The fate of injected mucopolysaccharides","volume":"41","author":"Kaplan","year":"1962","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymgme.2014.10.012_bb0180","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1542\/peds.2008-0416","article-title":"Mucopolysaccharidosis I: management and treatment guidelines","volume":"123","author":"Muenzer","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2014.10.012_bb0185","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ymgme.2008.10.009","article-title":"A dose-optimization trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I","volume":"96","author":"Giugliani","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2014.10.012_bb0190","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10545-009-9036-3","article-title":"Dermatan sulfate and heparan sulfate as a biomarker for mucopolysaccharidosis I","volume":"33","author":"Tomatsu","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2014.10.012_bb0195","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.1074\/jbc.M110.192062","article-title":"Secondary storage of dermatan sulfate in Sanfilippo disease","volume":"286","author":"Lamanna","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2014.10.012_bb0200","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.bbamcr.2008.11.014","article-title":"Secondary lipid accumulation in lysosomal disease","volume":"1793","author":"Walkley","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgme.2014.10.012_bb0205","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1369\/0022155412459857","article-title":"Iduronic acid in chondroitin\/dermatan sulfate: biosynthesis and biological function","volume":"60","author":"Malmstr\u00f6m","year":"2012","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.ymgme.2014.10.012_bb0210","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1172\/JCI200113560","article-title":"Heparan sulfate proteoglycans: intricate molecules with intriguing functions","volume":"108","author":"Iozzo","year":"2001","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymgme.2014.10.012_bb0215","doi-asserted-by":"crossref","first-page":"117R","DOI":"10.1093\/glycob\/cwf066","article-title":"Dermatan sulfate: new functions from an old glycosaminoglycan","volume":"12","author":"Trowbridge","year":"2002","journal-title":"Glycobiology"},{"key":"10.1016\/j.ymgme.2014.10.012_bb0220","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/joim.12061","article-title":"Pathophysiology of heparan sulphate: many diseases, few drugs","volume":"273","author":"Lindahl","year":"2013","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.ymgme.2014.10.012_bb0225","first-page":"132","article-title":"Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I\/II clinical trial","volume":"3","author":"Amalfitano","year":"2001","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2014.10.012_bb0230","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2014.10.012_bb0235","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/gim.2011.4","article-title":"Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease","volume":"14","author":"Messinger","year":"2012","journal-title":"Genet. Med."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719214003382?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719214003382?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T07:11:44Z","timestamp":1598425904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719214003382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S1096719214003382"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2014.10.012","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarker responses correlate with antibody status in mucopolysaccharidosis type I patients on long-term enzyme replacement therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2014.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}